Company intelligence / Profile preview

Akuo

Boston, Massachusetts, United Statesakuoenergy.com ↗

Ownership: Private
Employees: ~57
Development stage: Commercial

Overview

Akouos developed a pipeline of AAV-mediated gene therapies targeting genetic forms of hearing loss. Its lead candidate AK‑OTOF received FDA clearance for clinical testing and entered a Phase I/II trial designed to treat sensorineural hearing loss caused by OTOF mutations. Other programs target additional genetic causes of deafness and vestibular disorders. The company was acquired by Eli Lilly in late 2022 for up to $610 million

Therapeutic areas: Rare DiseasesNeurology
Modalities: Gene therapyAdeno-associated virus (AAV) vector-based therapyBiologic (for gene delivery)
Industry: Biotech

Partnerships

Now part of Eli Lilly’s broader genetic medicine strategy; no major external pharma partnerships disclosed prior.

Beyond the preview

Go deeper on Akuo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akuo.

Explore the full profile